Rheumatology

Defined cut-off scores for patient function and MRI-detected bone erosion may potentially help clinicians and patients with rheumatoid arthritis (RA) in remission decide when to stop treatment.

According to the authors, this is the first study to approach methotrexate intolerance measurement from a patient perspective.

Version 5 of “COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Musculoskeletal Diseases" includes updated recommendations that differentiate supplemental and booster doses for people with rheumatic and musculoskeletal diseases (RMDs).

Patients with rheumatoid arthritis (RA) who used 3 or more targeted therapies, but not Janus kinase inhibitors, were at greater risk of developing herpes zoster, according to findings from a Korean study.

A patient with medication-induced severe acute generalized exanthematous pustulosis responded to treatment with secukinumab after unsuccessful courses of topical and systemic steroids.

A study found that antibody response against COVID-19 decreased by 2.8 times between months 1 and 6 post vaccination among people with rheumatic and musculoskeletal disease.

Patients with psoriasis who experienced secukinumab secondary failure did not require switching after experiencing significant improvement of daily functioning and quality of life when given a combination rescue therapy.

After analyzing past studies and classification criteria, authors found multiple factors that could be implemented into the current rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) tests for a more specific rheumatoid arthritis (RA) classification.

Women in the study were 3 times more likely to be affected by rheumatoid arthritis (RA) and nearly 4 times more likely to develop hypothyroidism, compared with men.

A study found that frailty reduced the likelihood of comprehensive disease control achievement by patients with rheumatoid arthritis (RA) being treated with a biologic agent.

Neither adalimumab nor secukinumab substantially affected a patient’s immune response to the Pfizer COVID-19 vaccine.

The safety profiles of COVID-19 vaccines in patients with inflammatory rheumatic and musculoskeletal disease (RMD) was comparable with patients with non-inflammatory RMD and the general population, according to a new study.

Investigation into myeloid-related protein 8/14 (MRP8/14) serves as an important next step of translational research to discovering a diagnostic biomarker for systemic juvenile idiopathic arthritis.

Readers were most interested in articles about cost of therapy, drug efficacy, and a unique case related to COVID-19.

A study of the adult Korean population found high salt intake was associated with an increase in major adverse cardiovascular events (MACE) in patients with rheumatoid arthritis (RA).

Secukinumab is approved for use among patients with enthesitis-related arthritis (ERA) aged 4 years and up, and those with psoriatic arthritis (PsA) who are at least 2 years old.

Stacy Courtnay is the community network chair for the Arthritis Foundation in Atlanta highlights a report that discusses how understanding patient experiences in RA can shift questions researchers ask.

With a low number of approved medications for pediatric plaque psoriasis, secukinumab is a valuable new addition to the limited treatment options available.

Study investigators saw sustained clinical response regardless of whether the participant with rheumatoid arthritis (RA) had discontinued the first tumor necrosis factor inhibitor (TNFi) due to a primary or secondary inefficacy.

Limited access to exercise equipment and facilities during lockdown appears to be a key reason for reduced physical activity levels.

Interstitial lung disease (ILD), created by inflammation that leads to scarring of the lungs, causes shortness of breath, dry cough, and fatigue; data show it doubles mortality risk in rheumatoid arthritis (RA).

Circulating Interleukin-11 is difficult to detect in healthy individuals, but when it is present in various inflammatory diseases, it has an elevated present in affected tissues, according to a literature review.

New research found that residual inflammation in ultrasound images was associated with patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA) with low disease activity, but not in patients in remission.

A new sub-analysis suggested eating foods with anti-inflammatory properties may improve physical functioning in patients with rheumatoid arthritis.

Abstracts from American College of Rheumatology Convergence 2021 showed whether gender can impact the effectiveness of secukinumab in patients with ankylosing spondylitis (AS) or psoriatic arthritis (PsA).

Data outline prevalence of COVID-19 breakthrough and long haul infections among patients with rheumatic diseases.

Biological markers collected early in the disease course of rheumatoid arthritis could help improve patient management, researchers said.

If FDA approved for children, secukinumab (Cosentyx) will be the first biologic treatment for children in the US living with enthesitis-related arthritis.

The most common health care disruption found in the study was the replacement of face-to-face consultations with over-the-phone appointments.

The review found an association between systemic inflammatory disorders and increased risk of cardiovascular disease, encouraging discussions with patients regarding statin therapy.